Coinheritance of Severe von Willebrand Disease With Glanzmann Thrombasthenia

Abstract

A 35-years old male patient presented severe bleeding was diagnosed to have type 3 von Willebrand disease (VWD) and carrier for Glanzmann thrombasthenia (GT). Propositus and family members were studied through basic coagulation tests and genomic DNA analysis. Two offspring of the family were diagnosed to have GT through platelet aggregation along with VWD carrier. The patient with VWD was found positive for homozygous truncating mutation R1659X in VWF gene, and all offspring were heterozygous carriers of null allele. Hence, propositus was a carrier of GT with severe type 3 VWD and wife was a carrier of GT. Thus, it is concluded that there is importance of careful studies of patients even from nonconsanguineous families to exclude unusual coinheritance of congenital hemostatic disorders. If single replacement therapy in patient not responding well then probably co-expression of coagulopathies required and multiple replacement therapy should be given according to clinical and laboratory features.

Keywords

von Willebrand Disease Glanzmann thrombasthenia bleeding phenotypes mutation

References

Sadler JE A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71(4):520-525.

Nurden AT , Caen JP An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. Br J Haematol. 1974; 28(2):253-260.

Phillips DR , Jenkins CS , Luscher EF , Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature. 1975;257(5527):599-600.

Asatiani E. , Kessler CM , and the Directors of the Comprehensive Hemophilia Treatment Centers in Region III. Multiple congenital coagulopathies co-expressed with Von Willebrand’s disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature. Haemophilia. 2007;13(6): 685-696.

Ivy AC , Nelson D. , Buchet G. The standardization of certain factors in the cutaneous ‘venostasis’ bleeding time technique. J Lab Clin Med. 1941 ;26(5):1812-1822.

Ahmad F. , Kannan M. , Biswas A. , Saxena R. Impact of 789Ala/Ala genotype on quantitative type von Willebrand Disease . Ann Hematol. 2009;88(5):479-483.

Macfarlane DE , Stibbe J. , Kirby EP , Zucker MB , Grant RA , McPherson J. A method for assaying von Willebrand factor (Ristocetin cofactor). Thromb Diath Haemorrh. 1975;34(1):306-308.

Sambrook J. , Fritsch EF , Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.

Schneppenheim R. , Brassard J. , Krey S. , et al. Defective dimerisation of von Willebrand factor subunits due to a Cys-Arg mutation in type IID von Willebrand disease . Proc Natl Acad Sci U S A. 1996;93(8):3581-3586.

10.

Mancuso DJ , Tuley EA , Westfield LA , et al. Human von Willebrand factor gene and pseudogene structural analysis and differentiation by polymerase chain reaction. Biochemistry . 1991;30(1):253-269.

11.

Purvis AR , Gross J. , Dang LT , et al. Two Cys residues essential for von Willebrand factor multimers assembly in the Golgi. Proc Natl Acad Sci U S A. 2007;104(40):15647-52.

12.

Rosenberg N. , Hauschner H. , Peretz H. , et al. A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3(12):2764-2772.

13.

Nounou R. , Spence D. Glanzmann’s thrombasthenia with mild von Willebrand’s disease . J Clin Pathol. 1993;46(12): 1134-1136.

14.

Nurden AT , Breillat C. , Jacquelin B. , et al. Triple heterozygosity in the integrin alphaIIb subunit in a patient with Glanzmann’s thrombasthenia. J Thromb Haemost . 2004;2(5):813-819.